(PHR) Phreesia - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US71944F1066
Stock: Software, Payments, Scheduling, Registration, Revenue Cycle
Total Rating 19
Risk 35
Buy Signal -0.71
| Risk 5d forecast | |
|---|---|
| Volatility | 46.2% |
| Relative Tail Risk | -5.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.27 |
| Alpha | -77.81 |
| Character TTM | |
|---|---|
| Beta | 1.628 |
| Beta Downside | 2.461 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.46% |
| CAGR/Max DD | -0.42 |
EPS (Earnings per Share)
Revenue
Description: PHR Phreesia March 04, 2026
Phreesia Inc. (PHR) operates a SaaS platform for the healthcare sector in the US and Canada. The company integrates software and payment processing, a common model in healthcare technology to streamline administrative tasks.
Its offerings include appointment scheduling, patient registration, and revenue cycle management, which encompasses insurance verification and payment collection. These services address critical operational needs for healthcare providers.
Phreesia deploys its platform across various modalities: mobile devices, dedicated tablets, web-based dashboards, and on-site kiosks. This multi-channel approach caters to diverse user preferences within healthcare settings.
The company serves a broad client base, from individual practices to large health systems, and also works with pharmaceutical, medical device, and biotechnology firms. This diversified client portfolio is typical for healthcare technology providers seeking broad market penetration. ValueRay offers further data-driven insights on companies like Phreesia.
Headlines to watch out for
- Healthcare provider adoption of SaaS platform drives recurring revenue
- Payment processing volume directly impacts revenue growth
- Regulatory changes in healthcare IT could increase compliance costs
- Competition from established EHR vendors pressures market share
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -5.38m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.08 > 1.0 |
| NWC/Revenue: 30.68% < 20% (prev 19.84%; Δ 10.84% < -1%) |
| CFO/TA 0.15 > 3% & CFO 61.4m > Net Income -5.38m |
| Net Debt (-102.9m) to EBITDA (26.4m): -3.89 < 3 |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.5m) vs 12m ago 6.22% < -2% |
| Gross Margin: 68.20% > 18% (prev 0.67%; Δ 6753 % > 0.5%) |
| Asset Turnover: 115.9% > 50% (prev 107.8%; Δ 8.09% > 0%) |
| Interest Coverage Ratio: -1.01 > 6 (EBITDA TTM 26.4m / Interest Expense TTM 2.24m) |
Altman Z'' -12.15
| A: 0.34 (Total Current Assets 240.9m - Total Current Liabilities 98.8m) / Total Assets 423.5m |
| B: -1.89 (Retained Earnings -800.5m / Total Assets 423.5m) |
| C: -0.01 (EBIT TTM -2.26m / Avg Total Assets 399.6m) |
| D: -7.76 (Book Value of Equity -800.2m / Total Liabilities 103.1m) |
| Altman-Z'' Score: -12.15 = D |
Beneish M -3.32
| DSRI: 0.80 (Receivables 88.3m/96.5m, Revenue 463.2m/405.1m) |
| GMI: 0.98 (GM 68.20% / 67.14%) |
| AQI: 0.90 (AQ_t 0.38 / AQ_t-1 0.42) |
| SGI: 1.14 (Revenue 463.2m / 405.1m) |
| TATA: -0.16 (NI -5.38m - CFO 61.4m) / TA 423.5m) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of PHR shares?
As of March 09, 2026, the stock is trading at USD 12.05 with a total of 1,078,661 shares traded.
Over the past week, the price has changed by -1.79%, over one month by -1.39%, over three months by -40.11% and over the past year by -45.15%.
Over the past week, the price has changed by -1.79%, over one month by -1.39%, over three months by -40.11% and over the past year by -45.15%.
Is PHR a buy, sell or hold?
Phreesia has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy PHR.
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.1 | 132.8% |
| Analysts Target Price | 28.1 | 132.8% |
PHR Fundamental Data Overview March 09, 2026
P/E Forward = 13.5318
P/S = 1.5683
P/B = 2.2679
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 623.6m USD (726.5m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 14.88x (Enterprise Value 623.6m / FCF TTM 41.9m)
FCF Yield = 6.72% (FCF TTM 41.9m / Enterprise Value 623.6m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 1.47 (Enterprise Value 623.6m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 11.95% (E(726.5m)/V(729.9m) * Re(11.91%) + D(3.48m)/V(729.9m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 11.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF] Terminal Value 54.77% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
[DCF] Fair Price = 4.17 (EV 148.3m - Net Debt -102.9m = Equity 251.2m / Shares 60.3m; r=11.95% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.22 | EPS CAGR: 139.3% | SUE: -0.29 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.35 | Chg7d=-0.001 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=7
EPS next Year (2027-01-31): EPS=1.50 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=+0 | Growth EPS=+28.8% | Growth Revenue=+15.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
P/S = 1.5683
P/B = 2.2679
Revenue TTM = 463.2m USD
EBIT TTM = -2.26m USD
EBITDA TTM = 26.4m USD
Long Term Debt = 3.35m USD (from longTermDebt, last quarter)
Short Term Debt = 6.20m USD (from shortLongTermDebt, last quarter)
Debt = 3.48m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.9m USD (from netDebt column, last quarter)
Enterprise Value = 623.6m USD (726.5m + Debt 3.48m - CCE 106.4m)
Interest Coverage Ratio = -1.01 (Ebit TTM -2.26m / Interest Expense TTM 2.24m)
EV/FCF = 14.88x (Enterprise Value 623.6m / FCF TTM 41.9m)
FCF Yield = 6.72% (FCF TTM 41.9m / Enterprise Value 623.6m)
FCF Margin = 9.05% (FCF TTM 41.9m / Revenue TTM 463.2m)
Net Margin = -1.16% (Net Income TTM -5.38m / Revenue TTM 463.2m)
Gross Margin = 68.20% ((Revenue TTM 463.2m - Cost of Revenue TTM 147.3m) / Revenue TTM)
Gross Margin QoQ = 68.40% (prev 67.90%)
Tobins Q-Ratio = 1.47 (Enterprise Value 623.6m / Total Assets 423.5m)
Interest Expense / Debt = 23.70% (Interest Expense 826.0k / Debt 3.48m)
Taxrate = 16.66% (854.0k / 5.12m)
NOPAT = -1.88m (EBIT -2.26m * (1 - 16.66%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 240.9m / Total Current Liabilities 98.8m)
Debt / Equity = 0.01 (Debt 3.48m / totalStockholderEquity, last quarter 320.3m)
Debt / EBITDA = -3.89 (Net Debt -102.9m / EBITDA 26.4m)
Debt / FCF = -2.45 (Net Debt -102.9m / FCF TTM 41.9m)
Total Stockholder Equity = 291.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.35% (Net Income -5.38m / Total Assets 423.5m)
RoE = -1.85% (Net Income TTM -5.38m / Total Stockholder Equity 291.3m)
RoCE = -0.77% (EBIT -2.26m / Capital Employed (Equity 291.3m + L.T.Debt 3.35m))
RoIC = -0.63% (negative operating profit) (NOPAT -1.88m / Invested Capital 300.7m)
WACC = 11.95% (E(726.5m)/V(729.9m) * Re(11.91%) + D(3.48m)/V(729.9m) * Rd(23.70%) * (1-Tc(0.17)))
Discount Rate = 11.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.50%
[DCF] Terminal Value 54.77% ; FCFF base≈41.9m ; Y1≈27.5m ; Y5≈12.6m
[DCF] Fair Price = 4.17 (EV 148.3m - Net Debt -102.9m = Equity 251.2m / Shares 60.3m; r=11.95% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 90.22 | EPS CAGR: 139.3% | SUE: -0.29 | # QB: 0
Revenue Correlation: 98.14 | Revenue CAGR: 21.47% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.35 | Chg7d=-0.001 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=7
EPS next Year (2027-01-31): EPS=1.50 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=+0 | Growth EPS=+28.8% | Growth Revenue=+15.1%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)